Fleming, G. Alexander
Petrie, John R.
Bergenstal, Richard M.
Holl, Reinhard W.
Peters, Anne L.
Heinemann, Lutz
Article History
First Online: 5 December 2019
Duality of interest
: No honoraria were received by members of the ADA–EASD Diabetes Technology Committee (AEDTC) for writing this manuscript or associated meetings. Most of the members of the AEDTC work with industry as listed below; however, the industry had no impact on the manuscript and its content.
: GAF is Executive Chairman of Kinexum, which advises multiple health-product companies in the fields of metabolism, cardiovascular, oncology and dermatology. He was formerly the Group Leader of the Division of Metabolism and Endocrine Drug Products at the US Food and Drug Administration (FDA). JRP has served on advisory boards for companies manufacturing pharmaceuticals used in the treatment of diabetes but no digital health companies. RMB has conducted clinical trials, consulted or served on the scientific advisory boards for Abbott Diabetes Care, Becton Dickinson, Bayer, Dexcom, Eli Lilly, Johnson & Johnson, Medtronic, Novo Nordisk, Roche Diabetes Care and Sanofi. He receives no personal income from these activities, for all payment goes to the non-profit Park Nicollet Institute. RWH coordinates the German/Austrian DPV initiative, which has been supported by Novo Nordisk, Medtronic, Roche, Boehringer-Ingelheim and Eli Lilly through institutional research grants. RWH did not receive any personal honoraria. ALP has served on advisory boards for Abbott Diabetes Care, Eli Lilly, Merck, Novo Nordisk, MannKind, Lexicon, Sanofi and Zafgen. She has received grant funding from AstraZeneca, MannKind and Dexcom. She has been on the Speaker’s Bureau for Novo Nordisk. LH is partner of Profil Institut für Stoffwechselforschung in Neuss, Germany, and of ProSciento in San Diego, CA, USA. He is a member of advisory boards for Roche Diagnostics, Abbott, Zense and Medtronic.
Free to read: This content has been made available to all.